Obinutuzumab

BNF:
8.2.3
Status:
Red
Decision Date:
July 2015
 

Comments

RED1,2,3: NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia.

RED1,2,3: NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab. (Decision date  - September 2017)

RED1,2,3: NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma. (Decision date  - April 2018)

RED1,2,3: NICE TA629: Obinutuzumab with bendamustine followed by obinutuzumab maintenance for treating follicular lymphoma that did not respond or progressed up to 6 months after treatment with rituximab  (Decision date - June 2020)

RED: SSC2579: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults) as per NHSE commissioning intentions (Decision - December 2023)

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app